Macromolecular NO‐Donor Micelles for Targeted and Augmented Chemotherapy against Prostate Cancer
Sign Up to like & getrecommendations! Published in 2022 at "Advanced Healthcare Materials"
DOI: 10.1002/adhm.202202266
Abstract: Mitoxantrone (MTO) is clinically utilized for treating hormone‐refractory prostate cancer (PCa), however, the therapeutic outcome is far from optimal due to the lack of proper drug carrier as well as the inherent MTO detoxification mechanisms… read more here.
Keywords: mto; prostate cancer; macromolecular donor;